Retevmo (selpercatinib) — United Healthcare
solid tumors with a RET gene fusion
Initial criteria
- Presence of RET gene fusion-positive solid tumor
- Disease is one of the following: recurrent OR advanced OR metastatic
Reauthorization criteria
- Patient does not show evidence of progressive disease while on Retevmo therapy
Approval duration
12 months